By Tony Fong

NEW YORK (GenomeWeb News) – A rapidly changing regulatory environment, slow adoption by clinicians, and the soft economy continue to be barriers to venture capital investments into the molecular diagnostics space, according to some VC investors and officials at MDx firms, with one venture capitalist calling the current environment one of the worst he's seen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.